We are live on ! Find out more

BioLife Solutions

BLFS

Market cap $1.72B

35.25 USD

-0.28

0.79%

At close Updated Sep 4, 4:00 PM EDT

1 day

-0.79%

5 days

-2.22%

1 month

8.39%

3 months

30.12%

6 months

70.54%

Year to date

47.55%

1 year

36.26%

5 years

-33.65%

10 years

1,869.27%

About: BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

Employees: 155

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 40%

Neutral 60%

Negative 0%

BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share in cash and 0.1442 shares of Repligen common stock.Halper Sadeh encourages BioLife shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whet.

BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders

Zacks Investment Research

BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to break-even earnings per share a year ago.

BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates

BioLife Solutions Reports Second Quarter 2026 Financial Results

Total revenue of $28.5 million, up 21% over Q2 2025 GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65% GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and non-GAAP adjusted EBITDA of $7.4 million, or 26% of revenue Repligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026 BOTHELL, Wash., Aug. 6, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three and six months ended June 30, 2026.

BioLife Solutions Reports Second Quarter 2026 Financial Results

The London Company Large Cap Vs. Russell 1000 Q2 2026 Portfolio Review

The London Company Large Cap portfolio returned 10.9% (10.7% net) during the quarter vs. a 15.1% increase in the Russell 1000 Index. ENTG was a top contributor, benefiting from improving fab utilization and accelerating AI-driven semiconductor demand. RSG declined despite another solid quarter as softer Environmental Solutions results and continued weakness in construction-related volumes weighed on investor sentiment.

The London Company Large Cap Vs. Russell 1000 Q2 2026 Portfolio Review

Diamond Hill Small Cap Fund Q2 2026 Portfolio Activity

Astrana Health outperformed as the company results have continued to demonstrate that it was not taking advantage of loopholes within Medicare coding. Magnolia Oil & Gas saw shares decline after an agreement was reached to end the war between the US and Iran and reopen the Strait of Hormuz. We initiated a position in Insteel Industries, the nation's largest manufacturer of steel wire reinforcing products for concrete construction.

Diamond Hill Small Cap Fund Q2 2026 Portfolio Activity

BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whe.

BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

Zacks Investment Research

Repligen to Expand Cell Therapy Capabilities With BioLife Buyout

RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.

Repligen to Expand Cell Therapy Capabilities With BioLife Buyout

BioLife Solutions to be acquired by Repligen in $1.5B cell therapy deal

BioLife Solutions, a Bothell, Wash.-based company developing tools for cell and gene therapy, is being acquired for $1.5 billion by the life sciences corporation Repligen.

BioLife Solutions to be acquired by Repligen in $1.5B cell therapy deal

Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach

Repligen NASDAQ: RGEN said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen's exposure to one of the faster-growing areas of bioprocessing.

Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS)

NEW YORK, July 22, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating BioLife Solutions, Inc. (NASDAQ: BLFS ) related to its sale to Repligen Corporation.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS)

See News Rankings

Price charts implemented using Lightweight Charts™